Frontlight ResearchEarly access
Active, not recruitingPhase 2
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
Key facts
- Who runs it
- Sunhawk Vision Biotech, Inc.
- Where
- Hillsboro, United StatesSee the siteAlso in 1 other country, 8 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 140 people enrolled
- Started
- 22 Jan 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SHJ002
- Atropine
- Record updated
- 23 January 2026
Who can take part
- Age
- 3 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Be male or female, age 3-12 years (inclusive)
- Cycloplegic sphere of -1.00 D or worse in both eyes
- Able to complete all study assessments and comply with the protocol
- Literate or able to orally communicate
- Parent or guardian able and willing to provide written informed consent
- Parent or guardian able and willing to assure subject compliance with the protocol, follow study instructions, and attend study visits
- Able to tolerate eye drops in both eyes
- Be able and willing to avoid all disallowed medications and refractive correction
- For female subjects of childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral oophorectomy]), a negative urinary test
- Women of childbearing potential must agree to use two reliable methods of contraception
- Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception
Who cannot take part
- Previous incisional or laser surgery
- Active or recent history of severe ocular infection or inflammation
- Axial length > 26 mm
- Anisometropia
- Astigmatism > 2.00 D
- Intraocular pressure > 21 mm Hg or < 6 mm Hg
- Any clinically significant finding on slit lamp biomicroscopy or ophthalmoscopy
Where in United States
Also in 1 other country, 8 sites
- Pacific Center for Advanced Vision Care Tanasbourne Vision CenterHillsboro, United States
About the trial
What the trial wants to find out
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control
Read full original descriptionShow less
SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
The 2 groups in the trial
- SHJ002Treatment being tested
The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.
- AtropineExisting treatment, for comparison
The assigned eyedrops will be instilled in both eyes once per day, one drop per application, 7 days a week, for 52 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study to Determine the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution on Myopia Control in Subjects Aged 3-12 Years.
- Record updated
- 23 January 2026